1Hayward C, Patel HC, Patel K, et al. (2016) The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. European heart journal Cardiovascular pharmacotherapy 2:90-94.

2Khan I, Patel HC, Nanayakkara S, Raju H, Voskoboinik A, Mariani JA (2018) Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997-2016. Internal medicine journal 48:427-432.

3Benjamin EJ, Blaha MJ, Chiuve SE, et al. (2017) Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 135:e146-e603.

4Rabinowich L, Shibolet O (2015) Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. BioMed research international :168905.

5Lewis JH, Ranard RC, Caruso A, et al. (1989) Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology (Baltimore, Md) 9:679-685.

6Zuckerman E, Lanir A, Sabo E, et al. (1999) Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. The American journal of gastroenterology 94:1613-1618.

7Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW (1987) Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Canadian journal of physiology and pharmacology 65:360-364.

8Dusman RE, Stanton MS, Miles WM, et al. (1990) Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82:51-59.

9Hussain N, Bhattacharyya A, Prueksaritanond S (2013) Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN cardiology 617943.

10Tsuda T, Tada H, Tanaka Y, et al. (2018) Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. Journal of medical case reports 12:95.

11Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. Jama 298:1312-1322.